News from PipelinereviewFollowNews from PipelinereviewStay current with all the latest and breaking news from Pipelinereview. Compare headlines and media bias behind news outlets on stories breaking today.Ground News has come across 539 headlines reported on by Pipelinereview during the past 3 months. Ground News rates Pipelinereview’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Pipelinereview’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow Stay current with all the latest and breaking news from Pipelinereview. Compare headlines and media bias behind news outlets on stories breaking today. Ground News has come across 539 headlines reported on by Pipelinereview during the past 3 months. Ground News rates Pipelinereview’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Pipelinereview’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about PipelinereviewWhere is Pipelinereview located?Pipelinereview's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top Pipelinereview NewsAlzheimerLeqembi Okayed for Subset of Early Alzheimer’s Patients100% Right coverage: 5 sourcesThe European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for Leqembi (lecanemab) to treat mild cognitive impairment and early Alzheimer’s disease, following a re-examination of the clinical data. The recommendation is only for patients who have one or no copies of the apolipoprotein E4 (APOE4) gene […]See the StoryFDA · United StatesFDA Approves First Menin Inhibitor for Acute LeukemiaCoverage: 2 sourcesThe FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older withSee the StoryAurora, Colorado · AuroraOncoVerity Raises Extended Series AOncoVerity, an Aurora, CO-based company which specializes in applying advanced bioinformatics to drug development, raised a Series A extension funding. The amount of the deal was not disclosed. The round was led by existing investors argenx and RefinedScience. Led by CEO Max Colao, OncoVerity applies computational tools to clinical and biological data to advance therapies for cancer patients. Through a strategic collaboration with Refined Scienc…See the StoryLatest News StoriesTopics Most Covered by pipelinereviewVaccinesAstraZenecaMerckMedicalHealthVaccinesAstraZenecaMerckSources Covering Similar Topicsstocktitan.netClinical Trials Arenaonclive.compressreach.comPharmacy Timesstocktitan.netClinical Trials Arenaonclive.comSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.
